
Benjamin Hofmeister
Articles
-
1 week ago |
multiplesclerosisnewstoday.com | Margarida Maia |Benjamin Hofmeister |Marisa Wexler
Biostate AI is partnering with the nonprofit Accelerated Cure Project (ACP) to develop a series of artificial intelligence (AI) models that can predict multiple sclerosis (MS) progression and how patients may respond to treatment. As part of the partnership, Biostate AI will use its high-throughput technology to profile RNA reads from ACP’s large collection of MS patient samples. RNA reads can be used as a measure of how active different genes are.
-
1 week ago |
multiplesclerosisnewstoday.com | Margarida Maia |Lindsey Shapiro |Benjamin Hofmeister |Marisa Wexler
Frexalimab, an experimental antibody-based medication, was well tolerated and maintained disease control over two years in adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from an open-label extension to a Phase 2 clinical trial (NCT04879628) in which frexalimab outperformed a placebo at reducing the number of active and new or enlarging brain lesions in adults with relapsing-remitting MS or active secondary progressive MS (SPMS) after 12 weeks.
-
3 weeks ago |
multiplesclerosisnewstoday.com | Marisa Wexler |Lindsey Shapiro |Benjamin Hofmeister
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease activity in mouse models of multiple sclerosis (MS), according to a study. The study was conducted by Neuron23, which is advancing a small molecule TYK2 inhibitor called NEU-627 to treat MS. That molecule is expected to enter early safety testing in healthy volunteers in the first half of this year.
-
3 weeks ago |
multiplesclerosisnewstoday.com | Ahna Crum |Marisa Wexler |Benjamin Hofmeister
Recently, my work-life balance felt off, so I took the opportunity to house-sit a family farm. I needed the solitude — the peace and quiet — to recharge. While there, I watched a flock of 50 to 60 goldfinches gather at the bird feeders daily. Their communal nature fascinated me, so I did a little reading on these bright yellow birds. Goldfinches, I learned, don’t defend a territory once they’ve started a family, which is unlike most birds.
-
1 month ago |
multiplesclerosisnewstoday.com | Lindsey Shapiro |Benjamin Hofmeister
Sarah Zichterman poses for a photo one year after her MS diagnosis. (Photos courtesy of Sarah Zichterman) Day 10 of 31This is Sarah Zichterman’s story:Getting diagnosed with MS was not something I thought would happen to me at age 24. One day in January 2024, I woke up and realized my vision felt a bit off, so I went to the emergency room to get checked out.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →